![Cell and antibody therapies targeting HLA-G](http://kactusbio.com/cdn/shop/articles/HLA-G_Clinical_Trial_Blog_1.png?v=1676398636&width=2800)
Cell and antibody therapies targeting HLA-G
On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001,...
Feb 14, 2023
![A next-generation immunotherapy target TNFR2](http://kactusbio.com/cdn/shop/articles/TNFR2_Blog.jpg?v=1676041757&width=2800)
A next-generation immunotherapy target TNFR2
The tumor necrosis factor (TNF) superfamily has important physiological significance in immune surveillance, tumor regression,...
Feb 10, 2023
![New Products February 2023](http://kactusbio.com/cdn/shop/articles/New_Products_January_Blog_Featured_Image_1.jpg?v=1675809619&width=2800)
New Products February 2023
Alkaline Phosphatase Alkaline Phosphatase (ALP) likely represents the most frequently assayed enzyme in all of...
Feb 07, 2023
![TIDES Asia 2023](http://kactusbio.com/cdn/shop/articles/TIDES_Asia2_2_b82565a7-0694-48e5-8fbd-f6e8c76e58cf.jpg?v=1675201078&width=2800)
TIDES Asia 2023
March 7-9th 2023: Meet us at TIDES Asia in Kyoto, Japan KACTUS will be at...
Jan 31, 2023
![GARP-TGF-β1 Monoclonal Antibody Clinical Trial Approved by FDA](http://kactusbio.com/cdn/shop/articles/GARP-TGF-B1_Blog.jpg?v=1674486700&width=2800)
GARP-TGF-β1 Monoclonal Antibody Clinical Trial Approved by FDA
On January 4, 2023, Shanghai Jiyu Pharmaceutical announced that the IND application for its Class...
Jan 23, 2023
![Focus on hematoma target FLT3](http://kactusbio.com/cdn/shop/articles/FLT3_Blog_Post.jpg?v=1673313019&width=2800)
Focus on hematoma target FLT3
About FLT3 Fms-like tyrosine kinase 3 (FLT3) is also known as CD135 (Cluster of differentiation...
Jan 09, 2023
![DKK1: A Wnt Pathway Regulator](http://kactusbio.com/cdn/shop/articles/DKK1_Blog_Post_3.jpg?v=1673023557&width=2800)
DKK1: A Wnt Pathway Regulator
DKK1 (Dickkopf-related protein 1, or Soggy) is a secreted glycoprotein that contains two conserved cysteine-rich...
Jan 06, 2023